

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 05D1000733	(X3) Date Survey Completed 05/18/2022
Name of Provider or Supplier Central Valley Pain Management And Wellness Clinic	Street Address, City, State 1300 Mable Ave Ste 2, Modesto, CA	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2110	<p>TOXICOLOGY CFR(s): 493.845(b)</p> <p>Failure to attain an overall testing event score of at least 80 percent is unsatisfactory performance.</p> <p>This STANDARD is not met as evidenced by: Based on the surveyor's review of the laboratory's records for evaluation of proficiency testing performance and an interview with laboratory personnel (LP) on 5/18/2022 between 11:30 a.m. and 12:30 p.m, it was determined that there were proficiency testing (PT) scores below 80 % for one Toxicology subgroup. The issue relates to Cycle 1 in 2022. Findings include: 1. On 5/18/22, an inspection was conducted between 11:30 a.m and 1:30 p.m. 2. During a review of the laboratory documentation from CAP (College of American Pathology- the agency providing the proficiency specimens), it was noted at approximately 12:30 p.m. that the laboratory had unacceptable Toxicology results as indicated below: 3. The findings and acceptable ranges were as follows: Cycle Q1 2022 Category: DMPM Specimen DMPM-02 Analyte Actual Result Expected Result (range) Oxycodone 418 132-273 Oxymorphone 529 139-267 Norfentanyl 142 67-140 4. The LP recognized the above results.</p>